Literature DB >> 18252847

Characterization and properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I.

Phu T Duong1, Ginny L Weibel, Sissel Lund-Katz, George H Rothblat, Michael C Phillips.   

Abstract

The contribution of ABCA1-mediated efflux of cellular phospholipid (PL) and cholesterol to human apolipoprotein A-I (apoA-I) to the formation of pre beta 1-HDL (or lipid-poor apoA-I) is not well defined. To explore this issue, we characterized the nascent HDL particles formed when lipid-free apoA-I was incubated with fibroblasts in which expression of the ABCA1 was upregulated. After a 2 h incubation, the extracellular medium contained small apoA-I/PL particles (pre beta 1-HDL; diameter = 7.5 +/- 0.4 nm). The pre beta 1-HDL (or lipid-poor apoA-I) particles contained a single apoA-I molecule and three to four PL molecules and one to two cholesterol molecules. An apoA-I variant lacking the C-terminal alpha-helix did not form such particles when incubated with the cell, indicating that this helix is critical for the formation of lipid-poor apoA-I particles. These pre beta 1-HDL particles were as effective as lipid-free apoA-I molecules in mediating both the efflux of cellular lipids via ABCA1 and the formation of larger, discoidal HDL particles. In conclusion, pre beta 1-HDL is both a product and a substrate in the ABCA1-mediated reaction to efflux cellular PL and cholesterol to apoA-I. A monomeric apoA-I molecule associated with three to four PL molecules (i.e., lipid-poor apoA-I) has similar properties to the lipid-free apoA-I molecule.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18252847      PMCID: PMC2311446          DOI: 10.1194/jlr.M700506-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  37 in total

Review 1.  High density lipoprotein structure.

Authors:  Sissel Lund-Katz; Lijuan Liu; Stephen T Thuahnai; Michael C Phillips
Journal:  Front Biosci       Date:  2003-05-01

Review 2.  Structural models of human apolipoprotein A-I: a critical analysis and review.

Authors:  C G Brouillette; G M Anantharamaiah; J A Engler; D W Borhani
Journal:  Biochim Biophys Acta       Date:  2001-03-30

3.  Delineation of the role of pre-beta 1-HDL in cholesterol efflux using isolated pre-beta 1-HDL.

Authors:  Dmitri Sviridov; Osamu Miyazaki; Kally Theodore; Anh Hoang; Isamu Fukamachi; Paul Nestel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-09-01       Impact factor: 8.311

4.  Domain structure and lipid interaction in human apolipoproteins A-I and E, a general model.

Authors:  Hiroyuki Saito; Padmaja Dhanasekaran; David Nguyen; Paul Holvoet; Sissel Lund-Katz; Michael C Phillips
Journal:  J Biol Chem       Date:  2003-04-22       Impact factor: 5.157

Review 5.  Structure-function relationships of apolipoprotein A-I: a flexible protein with dynamic lipid associations.

Authors:  Yves L Marcel; Robert S Kiss
Journal:  Curr Opin Lipidol       Date:  2003-04       Impact factor: 4.776

Review 6.  Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-10-30       Impact factor: 8.311

7.  Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux.

Authors:  Ginny L Weibel; Eric T Alexander; Michelle R Joshi; Daniel J Rader; Sissel Lund-Katz; Michael C Phillips; George H Rothblat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-07-05       Impact factor: 8.311

8.  Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol: formation of nascent high density lipoprotein particles.

Authors:  Lijuan Liu; Anna E Bortnick; Margaret Nickel; Padmaja Dhanasekaran; Papasani V Subbaiah; Sissel Lund-Katz; George H Rothblat; Michael C Phillips
Journal:  J Biol Chem       Date:  2003-08-19       Impact factor: 5.157

9.  Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization.

Authors:  Mark L Segall; Padmaja Dhanasekaran; Faye Baldwin; G M Anantharamaiah; Karl H Weisgraber; Michael C Phillips; Sissel Lund-Katz
Journal:  J Lipid Res       Date:  2002-10       Impact factor: 5.922

10.  Alpha-helix formation is required for high affinity binding of human apolipoprotein A-I to lipids.

Authors:  Hiroyuki Saito; Padmaja Dhanasekaran; David Nguyen; Els Deridder; Paul Holvoet; Sissel Lund-Katz; Michael C Phillips
Journal:  J Biol Chem       Date:  2004-03-12       Impact factor: 5.157

View more
  44 in total

1.  Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti inflammatory effects.

Authors:  Urbain Tchoua; Corina Rosales; Daming Tang; Baiba K Gillard; Ashley Vaughan; Hu Yu Lin; Harry S Courtney; Henry J Pownall
Journal:  Lipids       Date:  2010-10-24       Impact factor: 1.880

Review 2.  Hepatic ABCA1 and VLDL triglyceride production.

Authors:  Mingxia Liu; Soonkyu Chung; Gregory S Shelness; John S Parks
Journal:  Biochim Biophys Acta       Date:  2011-10-06

Review 3.  Three-dimensional models of HDL apoA-I: implications for its assembly and function.

Authors:  Michael J Thomas; Shaila Bhat; Mary G Sorci-Thomas
Journal:  J Lipid Res       Date:  2008-05-30       Impact factor: 5.922

Review 4.  Is ABCA1 a lipid transfer protein?

Authors:  Michael C Phillips
Journal:  J Lipid Res       Date:  2018-01-05       Impact factor: 5.922

Review 5.  Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection.

Authors:  Michael J Haas; Arshag D Mooradian
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

6.  Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1.

Authors:  John T Melchior; Scott E Street; Allison B Andraski; Jeremy D Furtado; Frank M Sacks; Rebecca L Shute; Emily I Greve; Debi K Swertfeger; Hailong Li; Amy S Shah; L Jason Lu; W Sean Davidson
Journal:  J Lipid Res       Date:  2017-05-05       Impact factor: 5.922

7.  Evacetrapib reduces preβ-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes.

Authors:  Yunqin Chen; Jibin Dong; Xiaojin Zhang; Xueying Chen; Li Wang; Haozhu Chen; Junbo Ge; Xian-Cheng Jiang
Journal:  Atherosclerosis       Date:  2019-04-14       Impact factor: 5.162

8.  Influence of apolipoprotein (Apo) A-I structure on nascent high density lipoprotein (HDL) particle size distribution.

Authors:  Charulatha Vedhachalam; Palaniappan Sevugan Chetty; Margaret Nickel; Padmaja Dhanasekaran; Sissel Lund-Katz; George H Rothblat; Michael C Phillips
Journal:  J Biol Chem       Date:  2010-08-02       Impact factor: 5.157

9.  High-Density Lipoprotein Proteomics: Identifying New Drug Targets and Biomarkers by Understanding Functionality.

Authors:  Scott Gordon; Anita Durairaj; Jason L Lu; W Sean Davidson
Journal:  Curr Cardiovasc Risk Rep       Date:  2010

10.  Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux.

Authors:  Sandhya Sankaranarayanan; John F Oram; Bela F Asztalos; Ashley M Vaughan; Sissel Lund-Katz; Maria Pia Adorni; Michael C Phillips; George H Rothblat
Journal:  J Lipid Res       Date:  2008-09-30       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.